Peginterferon beta-1a in multiple sclerosis: 2-year results from ADVANCE

OBJECTIVE: To evaluate the efficacy and safety of subcutaneous peginterferon beta-1a over 2 years in patients with relapsing–remitting multiple sclerosis in the ADVANCE study. METHODS: Patients were randomized to placebo or 125 µg peginterferon beta-1a every 2 or 4 weeks. For Year 2 (Y2), patients o...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Mult Scler
Main Authors: Kieseier, Bernd C, Arnold, Douglas L, Balcer, Laura J, Boyko, Alexey A, Pelletier, Jean, Liu, Shifang, Zhu, Ying, Seddighzadeh, Ali, Hung, Serena, Deykin, Aaron, Sheikh, Sarah I, Calabresi, Peter A
Formato: Artigo
Idioma:Inglês
Publicado em: SAGE Publications 2015
Assuntos:
Original Research Papers
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4512519/
https://ncbi.nlm.nih.gov/pubmed/25432952
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1352458514557986
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados